INTRODUCTION
Pancreatic neuroendocrine tumours (pNETs) are rare tumours accounting for 1% to 2% of all pancreatic neoplasms [1, 2] with a peak incidence in the ages between 30 to 60 years [3, 4] and a slight female preponderance. The identification of a pancreatic mass as a pNET remains challenging [5] but important as pNETs have a significantly better outcome as compared to other non-endocrine malignant tumours of the pancreas [6] . Pancreatic NETs typically present as solid neoplasms but can present as cystic tumours due to secondary degeneration (approximately 18% of pNETs) [7] . Cystic pNETs are more difficult to diagnose solely on imaging as the morphological characteristics are less distinct. Pancreatic NETs can be classified as functional and non-functional based on the hormones they secrete. The clinical diagnosis of functional tumours is easier compared to their non-functional counterpart [8] . Clinically, pNETs can either be benign or malignant with the incidence of malignancy being higher in the non-functioning pNETs [8] . In patients with functioning symptomatic pNETs, EUS and EUS-FNA has a significant role in the detection, precise localisation [6, 9, 10] and cytological confirmation of pNETs [6, 8, [11] [12] [13] . EUS can diagnose pNETs smaller than 1 cm [5] and can give a cytological diagnosis in up to 90% of cases [6, 8] .
Our aim was to assess the sensitivity of EUS and EUS-FNA for pNETs and compare performance over two consecutive J Gastrointestin Liver Dis, March 2015 Vol. 24 No 1: 69-75 4 year and 2 month periods, to investigate the comparative performance between solid and cystic pNETs and to assess the value of EUS and EUS-FNA in individuals with a pancreatic mass not diagnosed as a pNET after cross-sectional imaging.
MATERIAL AND METHODS
Freeman Hospital is a tertiary referral centre for hepatobiliary and pancreatic (HBP) diseases in the North East region of England with a catchment population of 3.5 million, undertaking approximately 900 pancreatico-biliary EUS procedures per year. This study was performed using routinely collected clinical data and, in accordance with the UK National Research Ethics Service guidelines, a formal ethical review was not required.
All EUS procedures were undertaken after obtaining informed patient consent, by two experienced endosonographers (K.W.O and M.K.N) who were not blinded to the results of previous radiological investigations. Hitachi EUB-7500 or Preirus US workstations (Hitachi Medical Systems, Wellingborough, UK) and Pentax linear echoendoscopes (Pentax, Slough, UK) were used to carry out a standard EUS assessment of the pancreatic lesions. Doppler imaging was used to identify and avoid blood vessels. On EUS imaging, solid pNETs were hypoechoic lesions with well defined margins and highly vascular while cystic pNETs appeared as anechoic lesions with a well defined margin. Cystic lesions could be unilocular, multilocular or mixed solid-cystic. FNA of the lesions was carried out under EUS guidance using 22 or 25 gauge FNA needles (Cook Medical , Limerick, Ireland). Direct smears were prepared from samples obtained from the solid pancreatic neoplasms by the endoscopist and were air-dried for May-Grunwald-Giemsa staining. Conventional smears and cytospins were used for cytological analysis between April 2003 and September 2007. Surepath liquid based cytology (LBC) preparation was used in all cases from September 2007 onwards. Ten different pathologists (including V.W.) were involved in reporting the FNA cytology of pancreatic aspirate in this series. Cytological diagnosis of solid pNETs was based on the following characteristics: dispersed cell population with eccentric cytoplasm smooth nuclear outline with saltpepper chromatin, inconspicuous nucleoli in the majority of cases and naked nuclei usually seen. Immunocytochemistry was performed on cytospins, previously stained conventional slides (Diff-Quick) or cell block. CD56, synaptophysin, Ki67, CK19, chromogranin and TTF1 were used for confirmation of pNETs. The tumours were graded using the standard Ki67 labelling index [14, 15] . Cyst fluid analysis was performed in cases of cystic pancreatic neoplasms for amylase and carcinoembryonic antigen (CEA). To prevent infection of cystic lesions, intravenous antibiotics were administered during EUS-FNA, and oral ciprofloxacin prescribed for a further 3 days. Final diagnosis of pNET was based on resection histology, biopsy histology or diagnostic cytology and imaging and raised pancreatic polypeptide in one patient. Tumours were assessed according to the World Health Organization classification [3] of gastroenteropancreatic neuroendocrine tumours and more recently by ENETS TNM staging that was introduced in 2006 [16] .
A retrospective review of our prospectively maintained EUS database was carried out over an eight year period between April 2003 and September 2011 to identify all patients who had undergone EUS for further investigation of solid and cystic pancreatic lesions detected on cross-sectional imaging and subsequently had a confirmed final diagnosis of pNET. Patients identified from the EUS database were cross referenced with a prospectively maintained HPB database in our hospital. Hospital records were reviewed to collect data for patient demographics, cross-sectional imaging studies before EUS, EUS findings and follow up. All patients were followed up for a period of at least 12 months. All imaging (CT, MRI and EUS), cytology and histology results were based on the official report.
Statistical analysis
Categorical variables are expressed as median, range or percentages and compared among groups using the chi-square test and Fisher's exact test. A p value of less than 0.05 was considered statistically significant. Cochran Q test was used to compare the sensitivity of cross-sectional imaging, EUS imaging, cytology and combined EUS and cytology in three different groups -solid pNETs, cystic pNETs and combined solid and cystic pNETs. Data was analysed using MedCalc 12.7 (MedCalc Software, Ostend, Belgium). If the Cochran Q test was positive (p<0.05), a test for pairwise comparison of variables according to Sheskin was automatically performed and a minimum required difference for a significant difference between two proportions was determined.
RESULTS

Solid pNET
One thousand and one hundred patients with solid pancreatic neoplasm underwent EUS-FNA during this period. Of these, 43 (3.9%) patients, who underwent a total of 51 EUS procedures, with a median of 3.0 passes (range 1-7), had a final diagnosis of solid pNET. Diagnosis was based on histology and cytology in 24, histology only in 11, cytology in seven and imaging and elevated pancreatic polypeptide in one. In 16 (37%) patients, cross-sectional imaging carried out for other reasons picked up an incidental pancreatic lesion. Fifteen (35%) presented with jaundice, 5 (11.5%) with weight loss, 5 (11.5%) with abdominal pain. In 2 (5%) the indication for the initial imaging could not be established. Three patients had a diagnosis of Type 1 MEN (multiple endocrine neoplasia) syndrome prior to a cytological diagnosis of pNET. One patient had a past medical history of neurofibromatosis (Von Recklinghausen disease). Five (11.6%) were functional tumours: 3 patients had somatostatinoma and 2 had gastrinoma (both in MEN Type 1 patients). Patient demographics and pNET dimensions are documented in Table I . The distribution was: head of pancreas 18 (42%), tail 10 (23%), body 5 (11.5%), ampulla 4 (9.5%), neck 3 (7%) and uncinate process 2 (4.5%). One (2.5%) patient had two lesions -one in the neck and one in the tail of the pancreas. Diagnostic performance is detailed in Table  I 
Cystic pNET
Three hundred and thirty four patients with cystic pancreatic neoplasm underwent EUS-FNA during the study period of which 10 (3%) had a final diagnosis of cystic pNETs and underwent a total of 15 EUS procedures with a median of 1 pass (range 1-6). Diagnosis was based on histology and cytology in 5, histology only in 3 and cytology only in 2. Indications for EUS were as follows: 6 (60%) patients presented with upper abdominal pain that led to crosssectional imaging which detected pancreatic cysts (although the relationship of cystic pNET to the symptom of abdominal pain was uncertain) and in 4 (40%) patients it was an incidental finding. All cystic pNETs in our study were non-functional. Patient demographics and pNET dimensions are documented in Table I .Cystic pNETs location is shown in Table II . Cyst morphology on EUS imaging was available for 9 patients (Table II) . On aspiration during EUS, cyst fluid appeared to be blood stained in 6 (60%), clear in 1 (10%), serous in 1 (10%) and no comment was made on the report in the remaining 9 (20%). Cyst fluid was viscous in 2 (20%), thin in 6 (60%) and data was not available in 2 (20%). Median CEA was 1.0 ng/ ml [n=5, range 1 to 2]. Median amylase level was 130 [n=5, range 42 to 1419]. Diagnostic performance is detailed in Table I . Sensitivity of cross-sectional imaging (CT/MRI) and EUS imaging in diagnosing a cystic pNET was 10% and 30%, respectively. Sensitivity of EUS-FNA was 60% while that of combined EUS imaging and EUS-FNA was 70%. Using the Cochran's Q test, we found a significant difference (Cochran's Q= 11.87 p=0.008) among the four diagnostic tests (CT/MRI, EUS imaging alone, EUS cytology alone and combined EUS imaging and cytology). Further test for pairwise comparison of variables revealed that a minimum difference of 51.65% was required and that the sensitivity of combined EUS imaging and cytology (70%) was significantly (p<0.05) higher than of CT/MRI (10%). One patient had a cytological diagnosis of adenocarcinoma. If the diagnosis of a neoplasm rather than a diagnosis of pNET was considered as true positive, thus including the adenocarcinoma as diagnostic, then the sensitivity of EUS-FNA alone would increase to 70% and the Thirty one (72%) out of 43 patients with solid pNETs had their scans reviewed in the HPB multidisciplinary team prior to EUS. A diagnosis of pNET was suggested in 18 (58%) of these. A diagnosis of NET was not made in any of the 12 patients not discussed in the HPB team prior to EUS. Regarding the 10 cystic pNETs, all cross-sectional imaging was reviewed in the HPB team prior to EUS. The diagnosis of pNET was suggested in one patient (10%).
Clinical impact of EUS
The additional benefit of EUS following non diagnostic cross-sectional imaging was evaluated. Of 25 solid masses without a diagnosis after cross sectional imaging, 19 (76.0%) were diagnosed as pNET based on EUS imaging and or cytology (Fig. 1) . If cases with inadequate aspirate are excluded, the incremental benefit increases to 86.3% (19 out of 22 patients). For cystic pNETs a diagnosis based on EUS imaging and or cytology was made in 66.7% (6 of 9) without a pre-procedural diagnosis of pNET (Fig. 2) .
DISCUSSION
Surgical and autopsy series suggest that pNETs can account for 0.8% to 10% of all pancreatic neoplasms [17] . Pancreatic NETs can occur sporadically or associated with inherited syndromes such as multiple endocrine neoplasia (MEN 1), Von Hippel Lindau disease, Von Recklinghausen disease and tuberosclerosis [18] . Clinically apparent pNETs can occur in up to 30% of cases of MEN 1 syndrome and subclinical pNETs in up to 80% [14] . Well differentiated pNETs are slow growing tumours with a better prognosis than pancreatic adenocarcinoma -hence, the pre-operative diagnosis of pNETs is important. The sensitivity of CT in detecting pNETs varies between 64% and 82% depending on the size of the tumour and that of MRI varies between 74% and 100% for large tumours [19] . For tumours less than 2 cm in size, EUS imaging alone is superior to CT and MRI for detecting and localising pNETs. Wamsteker et al. reported that in asymptomatic MEN 1 patients, EUS was able to detect 82% of pNETs before the onset of biochemical abnormalities [14] . EUS-FNA increases the diagnostic accuracy by providing cytology and can also differentiate between benign and malignant pNETs thereby guiding treatment.
Pancreatic NETs can be solid or cystic (8-17% of all pNETs) tumours [7, 20] . On EUS, solid pNETs usually appear as well defined hypoechoic, round, homogeneous, hypervascular lesions. They may be isoechoic and less commonly hyperechoic with irregular margins. Clinically, malignant pNETs are usually larger compared to their clinically benign counterparts. The differential diagnosis of solid pNETs includes adenocarcinoma (irregular hypoechoic mass with ill-defined margin), pseudo papillary tumour (lesions are well demarcated; they may appear as solid, or mixed solid and cystic, with or without septation; peripheral calcification is often present), acinar cell carcinoma (large, well circumscribed, partly encapsulated lesion occasionally with areas of haemorrhage and necrosis) and metastasis from other organs (homogeneous, round and well circumscribed lesions). Cystic pNETs may be unilocular, septated or mixed solid-cystic. Cystic pNETs are said to be more commonly associated with MEN 1 syndrome (3.5 times compared to solid pNETs) [7] . Most cystic pNETs are nonfunctional (approximately 80%) [7] . The differential diagnosis of cystic pNETs includes pseudocyst (usually large, unilocular, and anechoic with thin wall at early stage and thick walled at a later stage), macrocystic serous cystadenoma (unilocular usually thin wall), mucinous cystadenoma (usually macrocystic lesion greater than 2 cm with peripheral calcification in some cases).
In our study, the median age of diagnosis of pNETs was 64 years. Overall, there was a slight male preponderance (58.4%) compared to female preponderance in previous studies [3, 4] . None of the cystic pNETs was associated with MEN 1 syndrome whilst 3 of the solid pNETs were associated with MEN 1 syndrome. All cystic pNETs in our study were non-functional. In comparison to solid pNET, the diagnosis of cystic pNET is more difficult to make on imaging alone, whether by CT, MRI or EUS, due to the lack of distinguishing characteristics. This is reflected in our study where the sensitivity of cross-sectional imaging and EUS imaging in the diagnosis of cystic pNETs were 10% and 30%, respectively, compared to 41.8% and 58%, respectively, in the solid pNET cohort.
In our study, the overall sensitivity of EUS-FNA alone in the diagnosis of solid pNETs was 72%, combining EUS and EUS-FNA the sensitivity was 81%. Previous studies have reported a EUS-FNA sensitivity between 80% and 90% [6, [11] [12] [13] .The cytological yield in our series improved from 59% between 2003 and 2007 to 80.7% between 2008 and 2011. The improvement in our figures is possibly due a combination of the following factors: increased awareness among endosonographers and cytopathologists, use of LBC for processing and increasing the number of categorical diagnosis by reducing the number of samples categorised as atypical or suspicious [21] [22] [23] .
Earlier studies suggested that sensitivity might increase to 100% in cystic pNETs [20, 24, 25] if LBC and immunocytochemistry are employed. However, these were small studies (n=9) and more recent literature suggests a diagnostic yield varying between 60% and 70%. A recent multicentre study by Ho et al. [26] reported on 27 cases of cystic pNETs. EUS-FNA sensitivity in this series was 71%. Another study by Yoon et al. [27] reporting on 19 cases of cystic pNETs, documented a EUS-FNA yield of 63.2%. A further study by Morales-Oyarvide et al. [15] reporting on 33 cases of cystic pNETs, documented a EUS-FNA yield of 71%. In our study, the yield of EUS-FNA alone in the diagnosis of cystic pNETs was 60%, combined with EUS the sensitivity was 70%. The yield increased from 20% between 2003 and 2007 to 100% between 2008 and 2011 . Whilst the number of cases is too small to draw any definitive conclusions this improvement in diagnostic performance is possibly due to a combination of increased awareness among endosonographers and cytopathologists, and in addition, a reduction in unsatisfactory aspirates through the use of LBC for processing. The median CEA was low (1.4 ng/ml) which is in accordance with previous studies [26] [27] [28] .
There are a number of potential pitfalls in the cytological diagnosis of pNET: in rare cases calcification, prominent nucleoli and greater pleomorphism may be seen. Macrophages may also be seen in the background of cystic pNET. Heavily blood stained FNAs require careful screening so as not to miss a case. Greater use of immunocytochemistry may be needed in cases lacking classical morphology. The immunocytochemistry used will depend on the other differential diagnoses under consideration, e.g. pancreatic adenocarcinoma, acinar cell carcinoma, and pseudopapillary tumour.
Contrast enhanced harmonic endoscopic ultrasonography (CH-EUS) is a novel technique utilizing a blood pool contrast agent (encapsulated microbubbles) that strongly increases the US backscatter and is therefore useful in the enhancement of echogenicity for the assessment of blood flow. In CH-EUS the US workstation is set to detect the harmonic of the fundamental scanning frequency and the signal from tissue is filtered out. This technique can detect relatively low volume and slow blood flow. Pancreatic adenocarcinoma is said to show a hypoenhancing pattern whilst pNET are hyper-enhancing [29, 30] . CH-EUS thus may have a role in differentiating solid pNET from pancreatic ductal adenocarcinoma.
We found that review of imaging by an HPB radiologist prior to EUS correctly identified 58% of solid cases. This study does not purport to be a direct comparison between EUS and CT or MRI as the study methodology is inherently biased against cross-sectional imaging. EUS is not used routinely in our institution for pNETs diagnosed on CT, therefore a significant proportion of cases where a confident diagnosis of pNET was made on cross sectional imaging did not undergo EUS. In addition, the cross-sectional imaging protocols varied in different hospitals ranging from plain CT abdomen to pancreatic protocol CT and the MR scans varied from MRCP to MR pancreas. Not all images were reviewed by a specialist HPB radiologist prior to EUS which may be contributing reasons for the poor performance of CT and MRI overall compared with EUS.
However, we found a significant impact of EUS and EUS FNA in cases where cross sectional imaging had not made a diagnosis or had suggested a diagnosis other than pNET: 19 out of 25 patients (76.0%) with solid pNETs and 6 out 9 patients (66.7%) with cystic pNETs.
The main strength of our study is that the data collection was very robust. The main limitation is that it was a retrospective study. However, all patients who underwent EUS-FNA and had a final diagnosis of pNET were identified from our prospectively maintained EUS database. Being a retrospective study, the EUS report terminology was not standardised. Hence there is some non-uniformity regarding the reporting of the morphological characteristics with particular relevance to cystic pNETs. A minority of patients (12/43) with solid pNETs did not have their cross-sectional imaging reviewed by a specialist radiologist in the HPB MDT prior to EUS. This may have contributed to the low pre-EUS diagnosis of pNET in this cohort. The introduction of LBC in the middle of the study may have influenced the overall cytological yield in the two phases of the study period.
CONCLUSIONS
EUS and EUS-FNA demonstrated good performances in diagnosing unsuspected pNETs. Overall, the yield of combined EUS imaging and cytology was significantly higher than that of CT and or MRI and the yield of combined EUS imaging and cytology was significantly better than EUS imaging alone.
EUS and EUS-FNA had a significant clinical impact in cases where a pNET was not suspected after cross-sectional imaging.
